[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@plainyogurt21 Avatar @plainyogurt21 Adu Subramanian

Adu Subramanian posts on X about $abvx, $bbio, $vrna, $xbi the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXXX% cryptocurrencies XXXX% finance XXXX% technology brands XXXX% currencies XXXX% countries XXXX%

Social topic influence $abvx 7.02%, $bbio 3.51%, $vrna 3.51%, $xbi 3.51%, doc 3.51%, imo 1.75%, $alny 1.75%, $eldn 1.75%, $cdtx 1.75%, $nktr XXXX%

Top accounts mentioned or mentioned by @amaymd @melvinriskmgmt @houndcl @desertdweller93 @joserestonva @justkissmyrezpe @a_may_md @dragonmaxgoku @17thfellow @sanctuarybio @aaronrosenblum5 @jeremyj0916 @avidresearch @jfais20 @seedy19tron @biotechcat @jinghanghu @a_a_free @ejliv850 @vulpescap

Top assets mentioned BridgeBio Pharma, Inc. Common Stock (BBIO) Bitcoin Incognito (XBI) Alnylam Pharmaceuticals, Inc. (ALNY) Cere Network (CERE) Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) Agios Pharmaceuticals, Inc. (AGIO) Eli Lilly and Company (LLY) AstraZeneca PLC (AZN) United Therapeutics, Corp. (UTHR) Celldex Therapeutics, Inc (CLDX)

Top Social Posts #

Top posts by engagements in the last XX hours

"@Vulpescap Only new news recently is the Oral Imatinib study. Showed improvements in PVR but only trend on 6MWD. Still don;t know how to explain Aerovate failure imo"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-14 16:05:54 UTC 4183 followers, XXX engagements

"$ALNY $BBIO and there we have it. Commercial policy from united healthcare requires prior ATTRUBY or VYNDA for using vutrisiran. Not a universal step edit but on the margins this cuts out a significant % of the population"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-06 15:28:39 UTC 4183 followers, 42.9K engagements

"Maybe people are finally looking at $ELDN R &D day"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-14 16:04:35 UTC 4178 followers, 2363 engagements

"Time to jinx it $XBI $VRNA $PROK $NKTR $CDTX to name a few"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-09 17:04:50 UTC 4183 followers, 1787 engagements

"$STOK Some math on the Biogen Deal and I think it works out to about 800M in peak ROW sales 700M market cap 380M cash. assumes XX% PoS from Biogen side"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-12 17:00:41 UTC 4183 followers, 5259 engagements

"@Sanctuary_Bio @AppleHelix @stockblues @A_May_MD @Sports_bios @AndyBiotech How many people have made theses on the back of X paid Y for this company $RETA $CERE $GBT (Im guilty of this one)"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-06 20:00:16 UTC 4182 followers, XXX engagements

"Good post on $ABVX. It's odd because I don't agree with any of the bear theses but I still don't own. Takes guts to go long a XX% downside readout THe real bear argument is that induction isn't good enough to bridge their cash runway and the enrollment times signal potential issues"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-14 16:01:53 UTC 4182 followers, 5839 engagements

"@rohitsjhawar @nikitabier I can't get a lot things without a doctor approval (like an MRI or covered blood work). The day I can will rarely need to see a doc"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-25 01:59:07 UTC 4182 followers, XXX engagements

"I don't think this expands the market: if you have the gene you will have the disease. but it will pull forward demand away from long term competition IF QURE shows a strong benefit (5 years slowing). I would be cautious about the eligible patient range and FDA label for it. If it's not on label (becuase not in the trial) then no way insurance covers it"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-17 20:20:32 UTC 4178 followers, XXX engagements

"@Sanctuary_Bio @JoseRestonVA @synapse_surfer Thats the type of commentary which gets my spider sense tingling I need to see more What do you want to see before your opinion changes"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-25 19:22:28 UTC 4183 followers, XXX engagements

"Spent some time on $ABVX and a few thoughts 1) the drug is clearly active. YOu can't fake endoscopic responses in my opinion. THe drug works to induce some sort of real effect. 2) pretty certain the moa is via MiR-124 -STAT3 - inhibit TH17. Interestingly enough shifting the phenotype away from Th17 is likely how nicotine works to treat UC and why smokers are protected vs US 2a) the lack of effect on cytokines is fine actually. IL17 is the main th17 specific cytokine and they show an effect there. 3) I think the maintenance data is great but induction data is meh. They have to raise on"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-03 21:11:27 UTC 4182 followers, 6848 engagements

"$NAMS Underrated commercial bull thesis vs lp(a) and PCSK9 is type of doc for the patient. CETP can be used by PCP comfortable with orals and the billin while any injectable is handoff to the cardiology Further if they do reduce alzheimer's risk it's an easy sell"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-17 20:01:19 UTC 4183 followers, 2455 engagements

"@AB1001_disciple @DesertDweller93 When would alnylam be set for approval"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-17 14:39:10 UTC 4183 followers, XXX engagements

"For $ABVX to be up XXX% what is the remission rate needed"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-19 22:29:05 UTC 4181 followers, 9963 engagements

"Yes I did not enough of course. My X% position pales in comparison to the balls on the other bulls"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-22 22:21:44 UTC 4182 followers, 5422 engagements

"while we start ascribing too. much value to anecdotes here's a patient in $QURE Study: "I regret being part of the study.""
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-18 18:32:51 UTC 4183 followers, 8933 engagements

"$AGIO Can someone explain how these stats calculations work Going through recent conference for sickle cell disease and they say XX% power with .02 alpha to detect XX% hemoglobin response rate improvement. total XXX patients (about). Does this look horribly overpowered ChatGPT explained like this: What am I missing"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-04-18 23:44:34 UTC 4182 followers, 1705 engagements

"$TECX $LLY $AZN. I think Volenrelaxin failed for two reasons. 1) wrong population. Acute decompensating HFpEF patients are not Group X PH. We had mixed evidence for relaxin in HF now we know it doesn't work. The renal selective vasodilation doesn't improve the mortality output enough 2) LARS as an endpoint is no bueno. I think this one is harder to grok. LARS is an echo endpoint a proxy for left atrial filling. Catheterization measures this a little more directly. Reducing volume overload should reduce LARS. but it's just a proxy. It's sown mixed results and the endpoint is noisy in HFpEF."
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-14 02:16:08 UTC 4182 followers, 4932 engagements

"Breaking down 20X turnarounds - acquisitions H/t @learnbiotech The potential common thread is some shitco with a bad readout then the stock price climbs about 4x before proof of concept trial readout and jumps on the PoC trial readout. Most companies are acquired once they disprove the major bear thesis whether commercial ($VRNA) or clinical phase 1/2 ($LBPH). I think it's a combination of 1) low expectations due to prior poor performance not IPOs. Some bad readout 2) a second act where investors are slow to recognize it 2a) potentially a bridge financing from reputable investors to try the"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-15 02:42:59 UTC 4183 followers, 11.2K engagements

"@A_May_MD I think the stat6 is the clear as day explanation. Picked up in a second and non obvious unless youve studied for step X and memorized how smoking makes UC better"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-21 18:13:08 UTC 4182 followers, 1157 engagements

"$LQDA $UTHR Interesting quirk here: Teton X is all US Teton X all ROW. TETON X reads out this year first. The ROW study started a year later and recruited faster. Could be an interesting scenario where Teton X is negative but TETON X is positive. Fibroneer Phase X study showed much higher (double the benefit) in asian patients. But TETON X only enrolls patient South america EU Taiwan. Wonder how much the SoC is different across geographies. Enrollment speed could be an indicator of excitement. EDIT: I think UTHR has ODD for X years in IPF. so not a catalyst for $LQDA. T/y to @bigpharmaguy"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-04 12:42:04 UTC 4182 followers, 3712 engagements

"So $CLDX what;s the bear case and why didn't the $JSPR debacle benefit them"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-10 01:41:16 UTC 4183 followers, 1957 engagements

"Happened after RFK Makary Prasad marks Layoffs Now sarepta. round and round we go New CDER hire looks good. One drug doesn't make an industry. $XBI $BBC"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-21 23:36:08 UTC 4176 followers, 4167 engagements

"@A_May_MD Been long $BBIO but tripling peak sales based on one KOL is wild"
@plainyogurt21 Avatar @plainyogurt21 on X 2025-07-15 00:06:01 UTC 4178 followers, 1378 engagements